Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies - PubMed
5 hours ago
- #Bronchiectasis
- #Microbiome
- #Precision Medicine
- Bronchiectasis is a heterogeneous chronic airway disease driven by infection, microbial dysbiosis, and host immunity dysregulation.
- Multi-omics technologies have revealed complex host-microbe interactions in bronchiectasis, beyond single pathogens.
- The field faces translational challenges, with microbiome data not yet leading to actionable diagnostics or therapies.
- Studies show common themes: low microbial diversity, pathogen dominance, loss of commensals, and neutrophil inflammation.
- Research integrates microbiome data with host inflammatory, proteomic, and immunophenotyping data to identify endotypes.
- Microbiome-modulating therapies are emerging, including biologics, bacteriophage therapy, and precision antibiotics.
- A roadmap is proposed for precision medicine via harmonized methods, biomarker integration, and multi-omics in registries.